Finn
TGTX Biotechnology · Commercial biotech · Multiple sclerosis · Single product · Thesis updated November 15, 2026

BRIUMVI momentum pushes TG Therapeutics to a billion dollar guide

01 Running thesis

A great launch pushing high expectations

TG Therapeutics is a focused biotech with one major product, BRIUMVI. The drug treats relapsing forms of multiple sclerosis, often called RMS. The third quarter of 2026 was exceptionally strong. U.S. BRIUMVI net product revenue hit $233 million, pushing global revenue to approximately $260 million for the quarter.

Management lifted full-year 2026 global revenue guidance to $1 billion, with U.S. revenue expected to fall between $915 million and $920 million. The company expects to exit the year above a $1 billion annualized run rate, fueled by record new patient starts.

The bull case relies on BRIUMVI expanding its share in the anti-CD20 market for MS. Its one-hour infusion is easy to explain to doctors and patients. The pipeline also supports the story. At the recent ECTRIMS meeting, the company shared positive seven-year follow-up data, success in a trial testing a simpler starting dose, and strong early data for a version of the drug injected under the skin.

The bear case is simple concentration. This is still a one-product company, and it competes with giants like Roche and Genentech. The Finn view notes that valuation risks remain. As the company crosses the billion-dollar threshold and takes on more debt, the stock requires flawless execution to keep climbing.

Nov 2026▲Q3 2026 U.S. sales hit $233 million. Management raised full-year global guidance to $1 billion and shared positive data de-risking the subcutaneous and simplified dosing pipeline.
Aug 2026▲Q2 2026 sales hit $228 million in the U.S. Management raised 2026 U.S. guidance to $890 million to $905 million and announced positive ENHANCE Phase 3 data.
May 2026▲Q1 2026 sales beat guidance at $195 million of U.S. BRIUMVI net product revenue. Management raised full-year 2026 U.S. revenue guidance.
May 2026→TG entered a new five-year credit facility with Blue Owl Capital and increased its share repurchase authorization to $300 million. This adds capital but also debt risk.
Feb 2026▲Full-year 2025 results showed $594 million from U.S. BRIUMVI net sales. Initial 2026 U.S. revenue guidance of $825 million to $850 million pointed to continued growth.
Nov 2025▲Q3 2025 U.S. BRIUMVI net sales reached about $153 million, and management raised 2025 U.S. revenue guidance again to about $585 million.
Aug 2025▲Q2 2025 revenue reached $139 million, up 15 percent quarter over quarter, and management raised 2025 U.S. revenue guidance. The company said BRIUMVI was capturing nearly one in three new IV anti-CD20 patients.
May 2025▲Q1 2025 U.S. BRIUMVI net sales were about $119.7 million, up 137 percent year over year. Management raised full-year 2025 U.S. net revenue guidance.
02 Business model

One MS drug funds the company

TG Therapeutics makes money by selling BRIUMVI in the United States and global markets. The drug is distributed mainly through specialty pharmacies and given in infusion centers. Its key pitch is that it offers an effective anti-CD20 MS therapy with a fast one-hour infusion time.

The company runs as a single business segment. Growth comes from adding new patients, keeping existing patients on the drug, and winning share from older therapies. Cash from BRIUMVI goes toward expanding the commercial effort and funding studies that could improve the drug label.

The company recently entered a new five-year credit facility. This $750 million senior secured credit facility brought in capital and allowed management to increase its share repurchase authorization to $300 million.

That capital plan works well while sales climb. However, more debt means the financial story is less forgiving if BRIUMVI growth slows down or if competitors win back market share.

03 Product portfolio

BRIUMVI and ways to extend it

Growth engine

BRIUMVI IV for relapsing MS

This is the approved product and the core business. It generated $233 million of U.S. net product revenue in Q3 2026.

Option

ENHANCE single-day starting dose

This study tested whether the first two IV starting doses can be combined into one. The trial met its endpoint and targets a mid-2027 label update.

Option

Subcutaneous BRIUMVI

This formulation would let patients receive the drug under the skin. After positive Phase 1 data, the company expects pivotal Phase 3 data around year-end 2026 or early 2027.

Option

Azer-cel

Azer-cel is an off-the-shelf CD19 CAR T-cell therapy being studied in progressive forms of MS, showing early safety and stability in Phase 1 trials.

Option

Myasthenia gravis study

The company is exploring BRIUMVI in myasthenia gravis with ongoing Phase 2 studies.

Option

Treatment-resistant schizophrenia study

This is an early exploratory effort outside the core MS market. It could broaden the company over time, but it is not central to near-term revenue.

04 Business segments

Mostly U.S. BRIUMVI sales

U.S. BRIUMVI net sales90%growing fast
Other global revenue10%modest

TG Therapeutics reports one operating segment. For Q3 2026, the company generated $233 million in U.S. BRIUMVI net product revenue out of approximately $260 million globally, making the U.S. business roughly 90 percent of the total.

05 Risk factors

What could break the thesis

BRIUMVI slowdown

High impact · Medium odds

The company depends heavily on one drug. If new starts slow, if patients stop therapy sooner than expected, or if payers tighten access, the raised 2026 guide could come under pressure. Expectations are now very high.

We watchQuarterly U.S. BRIUMVI revenue versus the $915 million to $920 million 2026 guidance range.

Roche and Genentech pressure

High impact · High odds

TGTX competes in the anti-CD20 MS market against much larger companies with deep sales reach. BRIUMVI has a clear convenience pitch, but rivals can respond with contracting, doctor outreach, or better delivery options.

We watchManagement comments on new patient share, pricing pressure, and account wins versus Roche and Genentech.

Subcutaneous data disappoints

Medium impact · Medium odds

A version injected under the skin could help BRIUMVI compete for patients who prefer at-home dosing. If the pivotal Phase 3 data is weak, that expansion path becomes less valuable. The IV franchise would remain important, but overall growth would slow.

We watchPivotal subcutaneous BRIUMVI top-line data expected around year-end 2026 or early 2027.

Debt limits flexibility

Medium impact · Medium odds

The new $750 million senior secured credit facility gives TG more capital and supports buybacks, but it increases debt. If revenue stalls, interest costs and repayment needs could limit research spending.

We watchCash balance, debt balance, interest expense, and the pace of the $300 million share repurchase authorization.

Manufacturing or tariff shock

Medium impact · Low odds

BRIUMVI is currently manufactured in South Korea. Management does not expect a material hit from currently proposed tariffs because the cost of goods is low. Still, a supply issue could hurt margins.

We watchFilings and earnings call comments on South Korea manufacturing, tariffs, inventory, and any second-source manufacturing updates.
06 Quick answers

In one breath

What does TG Therapeutics sell?

TG Therapeutics sells BRIUMVI, also called ublituximab. It is an anti-CD20 monoclonal antibody used to treat relapsing forms of multiple sclerosis.

Why did TGTX raise its 2026 guidance again?

The company reported $233 million of U.S. BRIUMVI net product revenue in Q3 2026. Management pointed to record new patient enrollments and treatment-naive patients making up nearly 40 percent of new starts.

What are the biggest upcoming catalysts for TGTX?

The company expects pivotal Phase 3 data for subcutaneous BRIUMVI around year-end 2026 or early 2027. It also expects a potential FDA approval for the simplified ENHANCE single-day starting dose by mid-2027.

Is TG Therapeutics profitable?

The internal view treats the company as solidly profitable after the BRIUMVI launch scaled, generating $86 million in Q3 operating income. The key question is whether profit growth can keep pace with debt, buybacks, and pipeline spending.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. TG Therapeutics Q3 2026 earnings call transcript
  2. TG Therapeutics Q2 2026 earnings call transcript
  3. TG Therapeutics Q1 2026 Form 10-Q
  4. TG Therapeutics Q1 2026 earnings call transcript
08 Explore the industry

Comparable Biotechnology companies

Companies near TG Therapeutics, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today